# Viridian Therapeutics, Inc.\DE (VRDN)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/viridian-therapeutics-inc-de/ JSON: https://steadybase.io/company/viridian-therapeutics-inc-de.json Checked Nov 10, 2026. Latest filing read: Nov 4, 2026.

## Company

- Legal name: Viridian Therapeutics, Inc.\DE
- Ticker: VRDN (Nasdaq)
- SEC CIK: 0001590750
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Waltham, MA
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: viridiantherapeutics.com
- LinkedIn: https://www.linkedin.com/company/viridiantx
- Next earnings date: Feb 5, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $70.8M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/0001590750-26-000007-index.html
- Operating income: -$363.4M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/0001590750-26-000007-index.html
- Net income: -$342.6M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/0001590750-26-000007-index.html
- SG&A: $95.3M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/0001590750-26-000007-index.html
- Employees: 252 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm
- Shares outstanding: 113,558,449 as of Nov 2, 2026 (10-Q filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000022/0001590750-26-000022-index.html
- Auditor: Kpmg LLP, Boston, Massachusetts, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm

## Business

We are a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases. We target therapeutic areas in which current treatments leave room for improvements in efficacy, safety, and/or dosing convenience. We believe there is significant potential in these areas, for better medicines that address unmet needs, improve outcomes, and expand treatment options for patients.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $70.8M | -$363.4M | -$342.6M | $95.3M |
| Dec 31, 2024 | $302,000 | -$299.0M | -$269.9M | $61.1M |
| Dec 31, 2023 | $314,000 | -$254.4M | -$237.7M | $95.0M |
| Dec 31, 2022 | $1.8M | -$134.3M | -$129.9M | $35.2M |
| Dec 31, 2021 | $3.0M | -$79.7M | -$79.4M | $25.8M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/viridian-therapeutics-inc-de.json

## Officers and directors

- Steve Mahoney, President and Chief Executive Officer of Viridian Therapeutics. LinkedIn: https://linkedin.com/in/steve-mahoney-92216b13. Source: 8-K filed Nov 4, 2026, https://www.sec.gov/Archives/edgar/data/1590750/000119312526446200/d176865dex991.htm
- Stephen F. Mahoney, President and CEO. Source: 4/A filed Mar 9, 2026, https://www.sec.gov/Archives/edgar/data/1590750/000119312526099007/0001193125-26-099007-index.htm
- Stephen Mahoney, President & Chief Executive Officer. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm
- Seth Harmon, Chief Financial Officer. LinkedIn: https://www.linkedin.com/in/seth-harmon-0a12b34. Source: 4/A filed Mar 9, 2026, https://www.sec.gov/Archives/edgar/data/1590750/000119312526099023/0001193125-26-099023-index.htm
- Thomas W. Beetham, Chief Operating Officer. LinkedIn: https://linkedin.com/in/thomas-beetham-85708020. Source: 4/A filed Mar 9, 2026, https://www.sec.gov/Archives/edgar/data/1590750/000119312526099014/0001193125-26-099014-index.htm
- Thomas Beetham, Chief Operating Officer. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm
- Jennifer Tousignant, Chief Legal Officer. LinkedIn: https://linkedin.com/in/jennifer-tousignant-3841902. Source: Form 4 filed Aug 20, 2026, https://www.sec.gov/Archives/edgar/data/1590750/000119312526359636/0001193125-26-359636-index.htm
- Radhika Tripuraneni, Chief Medical Officer. Source: Form 4 filed Aug 18, 2026, https://www.sec.gov/Archives/edgar/data/1590750/000119312526355735/0001193125-26-355735-index.htm
- Arlene M. Morris, Board member (per proxy). Source: DEF 14A filed Apr 17, 2026, https://www.sec.gov/Archives/edgar/data/1590750/000119312526160344/d904278ddef14a.htm
- Chris Cain, Ph.D., Board member (per proxy). Source: DEF 14A filed Apr 17, 2026, https://www.sec.gov/Archives/edgar/data/1590750/000119312526160344/d904278ddef14a.htm
- Jeff Ajer, Board member (per proxy). Source: DEF 14A filed Apr 17, 2026, https://www.sec.gov/Archives/edgar/data/1590750/000119312526160344/d904278ddef14a.htm
- Jennifer K. Moses, Board member (per proxy). Source: DEF 14A filed Apr 17, 2026, https://www.sec.gov/Archives/edgar/data/1590750/000119312526160344/d904278ddef14a.htm
- Radhika Tripuraneni, M.D., Chief Medical Officer. Source: DEF 14A filed Apr 17, 2026, https://www.sec.gov/Archives/edgar/data/1590750/000119312526160344/d904278ddef14a.htm
- Sarah Gheuens, M.D., Ph.D., Board member (per proxy). Source: DEF 14A filed Apr 17, 2026, https://www.sec.gov/Archives/edgar/data/1590750/000119312526160344/d904278ddef14a.htm
- Tomas Kiselak, Board member (per proxy). Source: DEF 14A filed Apr 17, 2026, https://www.sec.gov/Archives/edgar/data/1590750/000119312526160344/d904278ddef14a.htm

## Recent 8-K events

- Nov 4, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1590750/000119312526446200/d176865d8k.htm
- Aug 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1590750/000119312526336691/d174744d8k.htm
- Jun 29, 2026: Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1590750/000119312526286273/d164211d8k.htm
- Jun 3, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1590750/000119312526254560/d117727d8k.htm
- May 28, 2026: Item 1.02, Termination of a material definitive agreement. Source: https://www.sec.gov/Archives/edgar/data/1590750/000119312526245186/d111506d8k.htm
- May 26, 2026: Item 1.01, Entry into a material definitive agreement. Source: https://www.sec.gov/Archives/edgar/data/1590750/000119312526239246/d111034d8k.htm
- May 11, 2026: Item 1.01, Entry into a material definitive agreement; Item 2.03, Creation of a direct financial obligation; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1590750/000119312526216709/d154062d8k.htm
- May 5, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1590750/000119312526205099/d20977d8k.htm
- May 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1590750/000119312526205010/d149508d8k.htm
- Mar 30, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1590750/000119312526130433/d27955d8k.htm

## Insider trades (Form 4)

- Aug 19, 2026: Jennifer Tousignant (Chief Legal Officer) sold 14,212 shares, about $348,194. Source: https://www.sec.gov/Archives/edgar/data/1590750/000119312526359636/0001193125-26-359636-index.htm
- May 11, 2026: Funds Management LLC Fairmount (Director) bought 1,176,470 shares, about $20.0M. Source: https://www.sec.gov/Archives/edgar/data/1590750/000110465926060294/0001104659-26-060294-index.htm
- May 11, 2026: Healthcare Fund GP LLC Fairmount II (Director) bought 1,176,470 shares, about $20.0M. Source: https://www.sec.gov/Archives/edgar/data/1590750/000110465926060294/0001104659-26-060294-index.htm
- May 11, 2026: Healthcare Fund L.P. Fairmount II (Director) bought 1,176,470 shares, about $20.0M. Source: https://www.sec.gov/Archives/edgar/data/1590750/000110465926060294/0001104659-26-060294-index.htm
- Dec 31, 2025: Jennifer Tousignant (Chief Legal Officer) sold 2,272 shares, about $70,796. Source: https://www.sec.gov/Archives/edgar/data/1590750/000119312526001097/0001193125-26-001097-index.htm
- Oct 23, 2025: Healthcare Fund L.P. Fairmount II (Director) bought 454,545 shares, about $10.0M. Source: https://www.sec.gov/Archives/edgar/data/1590750/000110465925102606/0001104659-25-102606-index.htm
- Oct 23, 2025: Funds Management LLC Fairmount (Director) bought 454,545 shares, about $10.0M. Source: https://www.sec.gov/Archives/edgar/data/1590750/000110465925102606/0001104659-25-102606-index.htm
- Oct 23, 2025: Healthcare Fund GP LLC Fairmount II (Director) bought 454,545 shares, about $10.0M. Source: https://www.sec.gov/Archives/edgar/data/1590750/000110465925102606/0001104659-25-102606-index.htm

## What management said

- "We are highly encouraged by the strength of Lumvoa’s early launch in TED, which has exceeded expectations" Steve Mahoney, President and Chief Executive Officer of Viridian Therapeutics (8-K filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1590750/000119312526446200/d176865dex991.htm

## Latest filings

- 8-K filed Aug 6, 2026: https://www.sec.gov/Archives/edgar/data/1590750/000119312526336691/d174744d8k.htm
- 10-K filed Feb 26, 2026: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm
- 10-Q filed Aug 6, 2026: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000018/vrdn-20260630.htm
- DEF 14A filed Apr 17, 2026: https://www.sec.gov/Archives/edgar/data/1590750/000119312526160344/d904278ddef14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/